** Shares of drug developer Silexion Therapeutics SLXN.O fall 28.2% to $1.12
** SLXN says it is raising $5 mln through a public offering
** Public offering price is $1.35/share; 13.5% discount to the stock's last close
** Company plans to sue the proceeds to advance pre-clinical studies and for general corporate purposes
** H.C. Wainwright & Co. is the exclusive placement agent for the offering
** SLXN fell 88.3% in 2024 since its Nasdaq debut on Aug. 16, 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。